title: Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
abstract: Idelalisib (Zydelig®) is a first-in-class, orally administered, phosphatidylinositol 3-kinase-δ inhibitor that was recently approved for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin's lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL) in the USA and for the treatment of CLL and refractory follicular lymphoma in the EU. In a pivotal phase III trial in patients with relapsed CLL who were not able to receive cytotoxic agents, recipients of idelalisib plus rituximab had significantly improved progression-free survival, overall survival, overall response and lymph node response, compared with recipients of placebo plus rituximab. In a pivotal phase II trial, idelalisib monotherapy was effective in patients with relapsed indolent NHL who were refractory to rituximab and an alkylating agent, including in the subgroups of patients with follicular lymphoma or SLL. Oral idelalisib had a generally manageable adverse event profile, although episodes of serious/fatal diarrhoea or colitis, hepatotoxicity, pneumonitis and intestinal perforation were reported. In conclusion, idelalisib represents an important advance in the treatment of relapsed CLL and relapsed indolent NHL.
authors: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.
authors: Gillian M
authors: GM
authors: Keating
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011687:Purines / Q000627:therapeutic use*; D052999:Quinazolinones / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011687:Purines; D052999:Quinazolinones; C552946:idelalisib
references: N Engl J Med. 2014 Mar 13;370(11):1008-18
references: 24450858
references: Blood. 2012 Feb 23;119(8):1897-900
references: 22210877
references: PLoS One. 2013 Dec 23;8(12):e83830
references: 24376763
references: Blood. 2011 Sep 29;118(13):3603-12
references: 21803855
references: Clin Cancer Res. 2012 Aug 1;18(15):4013-8
references: 22711705
references: Front Immunol. 2012 Aug 09;3:224
references: 22908014
references: Blood. 2010 Sep 23;116(12):2078-88
references: 20522708
references: Blood. 2014 May 29;123(22):3390-7
references: 24615777
references: Curr Hematol Malig Rep. 2014 Mar;9(1):33-43
references: 24390602
references: N Engl J Med. 2014 Mar 13;370(11):997-1007
references: 24450857
references: Blood. 2011 Jan 13;117(2):591-4
references: 20959606
references: Blood. 2012 Oct 25;120(17):3501-9
references: 22955911
references: Blood. 2014 May 29;123(22):3406-13
references: 24615776
references: Blood. 2010 Sep 2;116(9):1460-8
references: 20505158
references: J Clin Oncol. 2012 Aug 10;30(23):2820-2
references: 22778323